NasdaqGS - Delayed Quote • USD
Rigel Pharmaceuticals, Inc. (RIGL)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 6:08 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.03 | -0.02 | -0.06 | 0.09 |
| Low Estimate | -0.04 | -0.03 | -0.13 | -0.02 |
| High Estimate | -0.01 | 0 | 0.04 | 0.18 |
| Year Ago EPS | -0.08 | -0.04 | -0.14 | -0.06 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 6 |
| Avg. Estimate | 31.28M | 33.1M | 148.99M | 192.17M |
| Low Estimate | 30.17M | 31.56M | 136.4M | 160M |
| High Estimate | 32.9M | 34.2M | 160.2M | 217.4M |
| Year Ago Sales | 26.07M | 26.89M | 116.88M | 148.99M |
| Sales Growth (year/est) | 20.00% | 23.10% | 27.50% | 29.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.1 | -0.08 | -0.07 | -0.03 |
| EPS Actual | -0.08 | -0.04 | -0.03 | 0 |
| Difference | 0.02 | 0.04 | 0.04 | 0.03 |
| Surprise % | 20.00% | 50.00% | 57.10% | 100.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.03 | -0.02 | -0.06 | 0.09 |
| 7 Days Ago | -0.03 | -0.02 | -0.06 | 0.09 |
| 30 Days Ago | -0.03 | -0.02 | -0.07 | 0.08 |
| 60 Days Ago | -0.04 | -0.03 | -0.09 | -0.02 |
| 90 Days Ago | -0.04 | -0.03 | -0.09 | -0.02 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RIGL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 62.50% | -- | -- | 1.60% |
| Next Qtr. | 50.00% | -- | -- | 10.50% |
| Current Year | 57.10% | -- | -- | 5.20% |
| Next Year | 250.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 70.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 3/7/2024 |
| Maintains | Cantor Fitzgerald: Neutral to Neutral | 3/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
| Maintains | B. Riley Securities: Neutral to Neutral | 3/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/22/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 |
Related Tickers
SLNCF Silence Therapeutics plc
8.00
0.00%
CRIS Curis, Inc.
14.31
-5.98%
LXRX Lexicon Pharmaceuticals, Inc.
1.6500
+1.23%
RNAC Cartesian Therapeutics, Inc.
17.91
+3.65%
SGMO Sangamo Therapeutics, Inc.
0.5115
+5.44%
TENX Tenax Therapeutics, Inc.
3.6300
-1.63%
AKBA Akebia Therapeutics, Inc.
1.3600
-2.16%
VINC Vincerx Pharma, Inc.
0.8500
-5.56%
CDTX Cidara Therapeutics, Inc.
0.6810
-5.68%
TRVN Trevena, Inc.
0.3520
-3.83%